News
06-23-2022, 06:34 PM
Breast cancers with HER2 mutations respond to the drug neratinib, but the responses are variable and often not durable.
More... (https://www.news-medical.net/news/20220623/Study-finds-a-more-effective-treatment-option-for-HER2-mutant-metastatic-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20220623/Study-finds-a-more-effective-treatment-option-for-HER2-mutant-metastatic-breast-cancer.aspx)